CStone Pharmaceuticals has announced the publication of a patent for its innovative antibody-drug conjugate, CS5006, which targets integrin β4, a protein linked to various aggressive cancers. The company is advancing this promising cancer therapy towards clinical development, with an Investigational New Drug application expected in 2025. This development underscores CStone's commitment to pioneering cancer treatments and highlights its robust pipeline of next-generation therapies.

For further insights into HK:2616 stock, check out TipRanks' Stock Analysis page.